Story perspectives

New Drug Combo Boosts Survival in Advanced Breast Cancer

2/4/2026

39 4

Summary

Story summary

The addition of palbociclib to standard treatments extended median progression-free survival to 44 months, versus 29 months with standard treatment, in patients with advanced triple-positive breast cancer.
The trial enrolled 518 patients across multiple countries.
Dr. Brittney Zimmerman, a breast medical oncologist, stated the combination could become a first-line treatment.
Pfizer funded the trial, and results were published January 28, 2026, in The New England Journal of Medicine.

1 of 1

Story summary

The addition of palbociclib to standard treatments extended median progression-free survival to 44 months, versus 29 months with standard treatment, in patients with advanced triple-positive breast cancer.
The trial enrolled 518 patients across multiple countries.
Dr. Brittney Zimmerman, a breast medical oncologist, stated the combination could become a first-line treatment.
Pfizer funded the trial, and results were published January 28, 2026, in The New England Journal of Medicine.